【荣昌生物绩前股价上涨 6.79%,现报 46.40 港元,成交额 3.99 亿港元。】美国临床肿瘤学会 2025 年年会将于 5 月 30 日至 6 月 3 日在美国芝加哥举行,荣昌生物 20 余项肿瘤管线临床进展或阶段性数据入选相关报告和展示。 国泰海通证券指出,RC48 联合疗法 1L 胃癌纳入 2025ASCO 口头汇报,看好其治疗潜力。此前 AAN 会议读出泰它西普 MG 的 III ...
Source Link【荣昌生物绩前股价上涨 6.79%,现报 46.40 港元,成交额 3.99 亿港元。】美国临床肿瘤学会 2025 年年会将于 5 月 30 日至 6 月 3 日在美国芝加哥举行,荣昌生物 20 余项肿瘤管线临床进展或阶段性数据入选相关报告和展示。 国泰海通证券指出,RC48 联合疗法 1L 胃癌纳入 2025ASCO 口头汇报,看好其治疗潜力。此前 AAN 会议读出泰它西普 MG 的 III ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.